RestructuringJun 18, 2026, 05:27 PM
Glass House Brands Deconsolidates Retail Business; Focuses on Medical Cannabis
AI Summary
Glass House Brands Inc. completed a Deconsolidation Transaction on June 12, 2026, segregating its dual-use cannabis business from its medical cannabis operations. This strategic move positions the company to capitalize on recent legislative changes, including the rescheduling of medical cannabis to Schedule III, which exempts operations from the 280E tax code and enables potential export and interstate commerce. The company is also expanding cultivation capacity, pursuing GACP compliance, and applying for export licenses, with 2026 production guidance of ~1 million pounds of cannabis biomass.
Key Highlights
- Completed Deconsolidation Transaction on June 12, 2026, segregating dual-use from medical cannabis business.
- Medical cannabis rescheduled to Schedule III in April 2026, exempting operations from 280E tax code.
- President Trump's Executive Order in December 2025 authorized Medicare CBD reimbursement program.
- Reimbursable CBD program creates a potential $35 billion government-funded addressable market.
- Accelerated buildout of Greenhouse 2 (fully planted) and Greenhouse 4 for hemp (initial sales June 2026).
- Registered cultivation/production with DEA and converted licenses for California Medical operations.
- Applied for export license and planning Greenhouse 3 build-out (>300K lbs. annual biomass capacity).
- 2026 Production Guidance: ~1 Million lbs. biomass, Revenues $235M-$245M, Adjusted EBITDA high $30M range.
Price Impact
More from GLASF